ArticleJournal of clinical laboratory analysis2020
Early diagnosis of breast cancer from exhaled breath by gas chromatography-mass spectrometry (GC/MS) analysis: A prospective cohort study.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Advanced strategy for cancer detection based on volatile organic compounds in breath.Journal of nanobiotechnology · 2025Pooled it
- Lipid Biomarkers in Glioma: Unveiling Molecular Heterogeneity Through Tissue and Plasma Profiling.International journal of molecular sciences · 2025Article
- Review
- Breathomics: A Non-Invasive Approach for the Diagnosis of Breast Cancer.Bioengineering (Basel, Switzerland) · 2025Review
- Utility of Volatile Organic Compounds and Electronic Nose Technology for Breast Cancer Detection: A Systematic Review.Breast cancer (Dove Medical Press) · 2025Review
- The human volatilome meets cancer diagnostics: past, present, and future of noninvasive applications.Metabolomics : Official journal of the Metabolomic Society · 2024Review
- Diagnosis of Carcinogenic Pathologies through Breath Biomarkers: Present and Future Trends.Biomedicines · 2023Review
- Article
- The Versatility and Diagnostic Potential of VOC Profiling for Noninfectious Diseases.BME frontiers · 2023Article
- GC-MS-based metabolomics of volatile organic compounds in exhaled breath: applications in health and disease. A review.Frontiers in molecular biosciences · 2023Review
- Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.PloS one · 2023Article
- Analysis of volatile organic compounds from deep airway in the lung through intubation sampling.Analytical and bioanalytical chemistry · 2022Article
- Distinguish oral-source VOCs and control their potential impact on breath biomarkers.Analytical and bioanalytical chemistry · 2022Article
- Development of a Non-invasive Diagnostic Method for Esophageal Squamous Cell Carcinoma by Gas Chromatographic Analysis of Exhaled Breath.Juntendo Iji zasshi = Juntendo medical journal · 2022Article
- Volatile Organic Compounds Analysis as a Potential Novel Screening Tool for Breast Cancer: A Systematic Review.Biomarker insights · 2022Review
- A prediction model using 2-propanol and 2-butanone in urine distinguishes breast cancer.Scientific reports · 2021Article
- Early diagnosis of breast cancer from exhaled breath by gas chromatography-mass spectrometry (GC/MS) analysis: A prospective cohort study.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has proved that there is an association between cancer and volatile organic compounds (VOCs) of exhaled breath. This study targets on verifying the existence of specific VOCs in breathing in breast cancer patients, especially those with ductal carcinoma in situ (DCIS).
methodsThere were a total of 203 participants included in the final analysis, which included 71 (35.0%) patients with histologically confirmed breast cancer (including 13 with DCIS, 31 with lymph node metastasis-negative status, and 27 with lymph node metastasis-positive status), 78 (38.4%) healthy volunteers, and 54 (26.6%) patients with histologically confirmed gastric cancer. Gas chromatography-mass spectrometry and solid-phase microextraction were used to analyze the breath samples for the presence of VOCs.
resultsThere were significant differences in the volatile organic metabolites between the DCIS, lymph node metastasis-negative breast cancer, and lymph node metastasis-positive breast cancer groups compared with the healthy controls as well as between the breast cancer and gastric cancer patients. An overlapping set of seven VOCs, including (S)-1,2-propanediol, cyclopentanone, ethylene carbonate, 3-methoxy-1,2-propanediol, 3-methylpyridine, phenol, and tetramethylsilane, was significantly different between the breast cancer patients and healthy individuals as well as between the breast cancer and gastric cancer patients. The combination of these seven compounds was considered as a biomarker for breast cancer. The sensitivity for predicting DCIS by this set of seven compounds was determined to be 80.77%, and the specificity was determined to be 100%.
conclusionsThis set of seven breast cancer-specific VOCs can be regarded as one particular expiratory marker for DCIS and will help to establish new screening methods for early breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.